Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral NNC0385-0434 dose-response study in ASCVD or ASCVD-risk patients requiring additional LDL-C lowering
2020-002630-32Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of NNC0385-0434 in atherosclerotic disease and hypercholesterolemia (5 arms), sponsored by Novo Nordisk. Primary endpoint: Change in LDL-cholesterol. Started May 2021; status: completed.
02
Drugs
NNC0385-0434
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on 2020-002630-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002630-32.